News - Boehringer Ingelheim, sofosbuvir

Filter

Popular Filters

1 to 25 of 193 results

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

15-04-2014

German family-owned drug major Boehringer Ingelheim today posted financial results for 2013, noting that,…

Boehringer IngelheimFinancialPharmaceutical

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

EMA/CHMP recommends empagliflozin for approval for type 2 diabetes

23-03-2014

German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

14-03-2014

US drugmaker Idenix Pharmaceuticals says it has filed patent infringement law suits against biotech firm…

Anti-viralsBiotechnologyGilead SciencesIdenix PharmaceuticalsLegalNorthern EuropePatentssofosbuvirSovaldi

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

“Differing views” see Zealand and Boehringer change collaboration compound

“Differing views” see Zealand and Boehringer change collaboration compound

20-01-2014

Zealand Pharma and Boehringer Ingelheim will change the development program involving novel glucagon/GLP-1…

Boehringer IngelheimDenmarkDiabetesGermanyPharmaceuticalResearchZealand Pharma

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

16-01-2014

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

FORMA meets milestones under Boehringer Ingelheim cancer accord

FORMA meets milestones under Boehringer Ingelheim cancer accord

10-01-2014

US drug discovery company FORMA Therapeutics revealed that it has achieved several discovery milestones…

Boehringer IngelheimFORMA TherapeuticsLicensingOncologyPharmaceuticalResearch

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

17-12-2013

New data show that family-owned German drug major Boehringer Ingelheim’s second-generation protease…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

Gilead’s Sovaldi approved in Canada for Genotypes 1, 2, 3 or 4 HCV

Gilead’s Sovaldi approved in Canada for Genotypes 1, 2, 3 or 4 HCV

16-12-2013

US antiviral biotech specialist Gilead Sciences says that Health Canada has issued a Notice of Compliance…

Anti-viralsBiotechnologyCanadaGilead SciencesNorth AmericaRegulationsofosbuvirSovaldi

1 to 25 of 193 results

Company Spotlight

Fibrotech

Fibrotech

Back to top